4  -0.6 (-13.04%)		10-15 16:00
Open: 4.6 High: 4.881 Volume: 24,350		Pre. Close: 4.6 Low: 3.705 Market Cap: 37(M)

Short term
Mid term
Targets	6-month :	6.69	1-year :	8.15
Resists	First :	5.73	Second :	6.98
Pivot price	5.4
Supports	First :	3.7	Second :	3.08
MAs	MA(5) :	4.69	MA(20) :	5.62
	MA(100) :	6.63	MA(250) :	9.28
MACD	MACD :	-0.5	Signal :	-0.4
%K %D	K(14,3) :	5.2	D(3) :	3.1
RSI	RSI(14): 18.5
52-week	High :	18.39	Low :	3.7

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ EXOZ ] has closed below the lower bollinger band by 8.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ EXOZ ] is to continue within current trading range. Bollinger Bands are 7.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	4.89 - 4.92	4.92 - 4.94
Low:	3.64 - 3.67	3.67 - 3.69
Close:	3.95 - 4	4 - 4.04

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

Sun, 11 Oct 2026
eXoZymes (EXOZ) Slips 1.50% to $5.25 as Shares Hold Above $5.00 Support - Bollinger Band - dars.gov.et

Fri, 02 Oct 2026
eXoZymes (EXOZ) Edges 1.20% Lower to $5.76 as Shares Hover Between Key Support and Resistance - Moving Average Crossovers - dars.gov.et

Sun, 20 Sep 2026
EXOZ: eXoZymes Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Thu, 17 Sep 2026
Exozymes (EXOZ) grants VP 45,000 stock options - Stock Titan

Tue, 08 Sep 2026
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT - Yahoo Finance

Tue, 08 Sep 2026
A 3,000-employee manufacturer will help eXoZymes move a product toward larger-scale production. - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	9 (M)
Shares Float	7 (M)
Held by Insiders	65.3 (%)
Held by Institutions	1.3 (%)
Shares Short	18 (K)
Shares Short P.Month	22 (K)

EPS	-1.2
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.38
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-74.8 %
Return on Equity (ttm)	-187.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.11
Qtrly Earnings Growth	0 %
Operating Cash Flow	-7 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-3.37
PEG Ratio	0
Price to Book value	10.25
Price to Sales	0
Price to Cash Flow	-5.32

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.